<?xml version='1.0' encoding='utf-8'?>
<document id="28411400"><sentence text="Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir."><entity charOffset="94-105" id="DDI-PubMed.28411400.s1.e0" text="Clopidogrel" /><entity charOffset="110-119" id="DDI-PubMed.28411400.s1.e1" text="Dasabuvir" /><pair ddi="false" e1="DDI-PubMed.28411400.s1.e0" e2="DDI-PubMed.28411400.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28411400.s1.e0" e2="DDI-PubMed.28411400.s1.e1" /></sentence><sentence text="Dasabuvir, a nonnucleoside NS5B polymerase inhibitor, is a sensitive substrate of cytochrome P450 (CYP) 2C8 with a potential for drug-drug interaction (DDI) with clopidogrel"><entity charOffset="0-9" id="DDI-PubMed.28411400.s2.e0" text="Dasabuvir" /><entity charOffset="162-173" id="DDI-PubMed.28411400.s2.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.28411400.s2.e0" e2="DDI-PubMed.28411400.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28411400.s2.e0" e2="DDI-PubMed.28411400.s2.e1" /></sentence><sentence text=" A physiologically based pharmacokinetic (PBPK) model was developed for dasabuvir to evaluate the DDI potential with clopidogrel, the acyl-β-D glucuronide metabolite of which has been reported as a strong mechanism-based inhibitor of CYP2C8 based on an interaction with repaglinide"><entity charOffset="72-81" id="DDI-PubMed.28411400.s3.e0" text="dasabuvir" /><entity charOffset="117-128" id="DDI-PubMed.28411400.s3.e1" text="clopidogrel" /><entity charOffset="134-154" id="DDI-PubMed.28411400.s3.e2" text="acyl-β-D glucuronide" /><entity charOffset="270-281" id="DDI-PubMed.28411400.s3.e3" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e0" e2="DDI-PubMed.28411400.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e0" e2="DDI-PubMed.28411400.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e0" e2="DDI-PubMed.28411400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e0" e2="DDI-PubMed.28411400.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e1" e2="DDI-PubMed.28411400.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e1" e2="DDI-PubMed.28411400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e1" e2="DDI-PubMed.28411400.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e2" e2="DDI-PubMed.28411400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28411400.s3.e2" e2="DDI-PubMed.28411400.s3.e3" /></sentence><sentence text=" In addition, the PBPK model for clopidogrel and its metabolite were updated with additional in vitro data"><entity charOffset="33-44" id="DDI-PubMed.28411400.s4.e0" text="clopidogrel" /></sentence><sentence text=" Sensitivity analyses using these PBPK models suggested that CYP2C8 inhibition by clopidogrel acyl-β-D glucuronide may not be as potent as previously suggested"><entity charOffset="82-114" id="DDI-PubMed.28411400.s5.e0" text="clopidogrel acyl-β-D glucuronide" /></sentence><sentence text=" The dasabuvir and updated clopidogrel PBPK models predict a moderate increase of 1"><entity charOffset="5-14" id="DDI-PubMed.28411400.s6.e0" text="dasabuvir" /></sentence><sentence text="5-1" /><sentence text="9-fold for Cmax and 1" /><sentence text="9-2" /><sentence text="8-fold for AUC of dasabuvir when coadministered with clopidogrel"><entity charOffset="18-27" id="DDI-PubMed.28411400.s10.e0" text="dasabuvir" /><entity charOffset="53-64" id="DDI-PubMed.28411400.s10.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.28411400.s10.e0" e2="DDI-PubMed.28411400.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28411400.s10.e0" e2="DDI-PubMed.28411400.s10.e1" /></sentence><sentence text=" While the PBPK results suggest there is a potential for DDI between dasabuvir and clopidogrel, the magnitude is not expected to be clinically relevant"><entity charOffset="69-78" id="DDI-PubMed.28411400.s11.e0" text="dasabuvir" /><entity charOffset="83-94" id="DDI-PubMed.28411400.s11.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.28411400.s11.e0" e2="DDI-PubMed.28411400.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28411400.s11.e0" e2="DDI-PubMed.28411400.s11.e1" /></sentence><sentence text="" /></document>